← Eichor
Study identifier: NCT07577817 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CTX001 in Healthy Adults.

Condition: Anemia · Iron Deficiencies · Chronic Kidney Disease  ·  Sponsor: Cajal Therapeutics Inc.

PhaseEARLY_Phase 1
Planned participants72
Who can joinAll sexes, 18 Years to 55 Years
Healthy volunteersYes

About this study

This study is testing CTX001 for certain conditions where the body does not have enough available iron or has difficulty storing or moving iron properly. The purpose of this study is to investigate any side effects that may happen with CTX001, how CTX001 is absorbed by and processed in the body, and how CTX001 affects iron levels in the blood when administered with or without iron and/or food.

This description comes directly from the study's public registry record.

Talk to the study team

Anthony Johnson  ·  +61 07 3707 2787  ·  a.johnson@nucleusnetwork.com.au

Always discuss trial participation with your own doctor first.

Locations (1)

Nucleus NetworkMelbourne, Victoria, AustraliaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07577817